The efficacy of fondaparinux for the prophylaxis of venous thromboembolism after resection for colorectal cancer

Hepato-Gastroenterology

Volumn 59, Issue 120, 2012, Pages 2477-2479

  Tsutsumi, Soichi ^a   Yajima, Reina ^a   Tabe, Yuichi ^a   Takaaki, ^a   Fujii, ^a   Morita, Hiroki ^a   Kigure, Wakako ^a   Kato, Toshihide ^a   Yamauchi, Hayato ^a   Suto, Toshinaga ^a   Asao, Takayuki ^a   Kuwano, Hiroyuki ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; Fondaparinux; Venous thromboembolism

Indexed keywords

FONDAPARINUX;

ADULT; AGED; ARTICLE; CANCER SURGERY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITALIZATION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; OPERATION DURATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; COLECTOMY; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERMITTENT PNEUMATIC COMPRESSION DEVICES; MALE; MIDDLE AGED; POLYSACCHARIDES; POSTOPERATIVE HEMORRHAGE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84872094497     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10295     Document Type: Article

References (12)

1. Heit JA: The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008; 28:370-372.
2. Prandoni P, Falanga A, Piccioli A: Cancer and venous thromboembolism. Lancet Oncol 2005; 6:401-410.
3. Murchison JT, Wylie L, Stockton DL: Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer 2004; 91:92-95.
4. Borly L, Wille-Jørgensen P, Rasmussen MS: Systematic review of thromboprophylaxis in colorectal surgery - an update. Colorectal Dis 2005; 7:122-127.
5. Osborne NH, Wakefield TW, Henke PK: Venous thromboembolism in cancer patients undergoing major surgery. Ann Surg Oncol 2008; 15:3567-3578.
6. Yu JL, May L, Lhotak V, et al.: Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105:1734-1741.
7. Lyman GH, Khorana AA, Falanga A, et al.: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25:5490-5505.
8. th ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126(3):338S-400S.
9. Leizorovicz A, Cohen AT, Turpie AG, et al.: Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110:874-879.
10. Cohen AT, Davidson BL, Callus AS, et al.: Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. BMJ 2006; 332:325-329.
11. Stender MT, Nielsen TS, Frekjaer JB, et al.: High preoperative prevalence of deep venous thrombosis in patients with colorectal cancer. Br J Surg 2007; 94:1100-1103.
12. Battistelli S, Genovese A, Gori T: Heparin-induced thrombocytopenia in surgical patients. Am J Surg 2010; 199:43-51.